Stay updated with breaking news from Michellen Rheault. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WEDNESDAY, Nov. 8, 2023 (HealthDay News) -- No significant differences are seen in the estimated glomerular filtration rate (eGFR) with sparsentan versus irbesartan among patients with focal segmental glomerulosclerosis (FSGS), according to a study published online Nov. 3 in the New England Journal of Medicine to coincide with Kidney Week, the annual meeting of the
Sparsentan reduced proteinuria to a significantly greater extent than irbesartan in patients with IgAN and FSGS.
Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney...
Investigators reported findings from the phase 3 PROTECT and DUPLEX trials. Sparsentan reduced proteinuria to a significantly greater extent than irbesartan in patients with IgAN and FSGS.
/PRNewswire/ -- The National Kidney Foundation (NKF) and its Kidney Disease Outcomes Quality Initiative (KDOQI) are pleased to announce the publication of the...